Abstract
Background: The Alzheimers Disease Assessment Scale – Cognitive Subscale (ADAS-Cog) has become the de facto gold standard for assessing the efficacy of anti-dementia treatments. However, manual administration of the ADAS-Cog is subject to procedural inconsistencies, including scoring and transcription errors, which can introduce unwanted variance and compromise data quality within and across sites and trials. To address such concerns, a computerized version was developed that integrates, rather than replaces, the examiner, standardizes administration, and uses electronic data capture at the point of patient contact. The examiner can control administration and pacing, pause or repeat digitized instructions, score verbal report and overt behavioral performance, and freely interact with the subject. Purpose: To conduct psychometric comparisons of traditional, paper-based administration of the standard ADAS-Cog (sADAS) with examiner- assisted administration of the computerized ADAS-Cog (cADAS). Methods: Eighty-eight patients (39M; 49F) with mild to moderate Alzheimers disease were tested on three occasions with each version over a period of one year with one month between paired visits. Results: Intraclass Correlation Coefficients (ICC) comparisons between sADAS and cADAS were significant for total score (ICC=0.96) and all subscores (ICCs ranged 0.78-0.93), with no significant differences on paired t-tests. The mean ICCs across cADAS scores for test-retest reliability for short-term (mean ICC=0.96) and long-term (mean ICC=0.91) comparisons were significantly higher than across sADAS scores (mean ICCs were 0.87 and 0.84, respectively). Conclusions: These results indicate that examiner-assisted, computerized administration is equivalent to traditional, paper-based administration, and shows significantly greater test-retest reliability.
Keywords: CMINDS, cognitive assessment, computerized ADAS-Cog, concurrent validity, clinical trials, psychometric comparison, test-retest reliability, Alzheimer's Disease Assessment Scale, ideational praxis, mild cognitive impairment, ADCS, NINCDS, ADRDA, MMSE
Current Alzheimer Research
Title: Psychometric Comparison of Standard and Computerized Administration of the Alzheimers Disease Assessment Scale – Cognitive Subscale (ADASCog)
Volume: 8 Issue: 3
Author(s): J. P. O'Halloran, A. S. Kemp, D. P. Salmon, P. N. Tariot and L. S. Schneider
Affiliation:
Keywords: CMINDS, cognitive assessment, computerized ADAS-Cog, concurrent validity, clinical trials, psychometric comparison, test-retest reliability, Alzheimer's Disease Assessment Scale, ideational praxis, mild cognitive impairment, ADCS, NINCDS, ADRDA, MMSE
Abstract: Background: The Alzheimers Disease Assessment Scale – Cognitive Subscale (ADAS-Cog) has become the de facto gold standard for assessing the efficacy of anti-dementia treatments. However, manual administration of the ADAS-Cog is subject to procedural inconsistencies, including scoring and transcription errors, which can introduce unwanted variance and compromise data quality within and across sites and trials. To address such concerns, a computerized version was developed that integrates, rather than replaces, the examiner, standardizes administration, and uses electronic data capture at the point of patient contact. The examiner can control administration and pacing, pause or repeat digitized instructions, score verbal report and overt behavioral performance, and freely interact with the subject. Purpose: To conduct psychometric comparisons of traditional, paper-based administration of the standard ADAS-Cog (sADAS) with examiner- assisted administration of the computerized ADAS-Cog (cADAS). Methods: Eighty-eight patients (39M; 49F) with mild to moderate Alzheimers disease were tested on three occasions with each version over a period of one year with one month between paired visits. Results: Intraclass Correlation Coefficients (ICC) comparisons between sADAS and cADAS were significant for total score (ICC=0.96) and all subscores (ICCs ranged 0.78-0.93), with no significant differences on paired t-tests. The mean ICCs across cADAS scores for test-retest reliability for short-term (mean ICC=0.96) and long-term (mean ICC=0.91) comparisons were significantly higher than across sADAS scores (mean ICCs were 0.87 and 0.84, respectively). Conclusions: These results indicate that examiner-assisted, computerized administration is equivalent to traditional, paper-based administration, and shows significantly greater test-retest reliability.
Export Options
About this article
Cite this article as:
P. O'Halloran J., S. Kemp A., P. Salmon D., N. Tariot P. and S. Schneider L., Psychometric Comparison of Standard and Computerized Administration of the Alzheimers Disease Assessment Scale – Cognitive Subscale (ADASCog), Current Alzheimer Research 2011; 8 (3) . https://dx.doi.org/10.2174/156720511795563692
DOI https://dx.doi.org/10.2174/156720511795563692 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Pharmacological Approaches to Prevent and Treat Post- Menopausal Osteoporosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The General Practitioners Role in Promoting Physical Activity to Older Adults: A Review Based on Program Theory
Current Aging Science Retraction Notice to Role of Vitamin K2 in the Treatment of Postmenopausal Osteoporosis
Current Drug Safety Good Epidemiologic Practice in Retinitis Pigmentosa: From Phenotyping to Biobanking
Current Genomics Microglial Integrity is Maintained by Erythropoietin Through Integration of Akt and Its Substrates of lycogen Synthase Kinase-3β, β-Catenin, and Nuclear Factor-κB
Current Neurovascular Research Sub-Chronic Exposure of Non-Observable Adverse Effect Dose of Terbufos Sulfone: Neuroinflammation in Diabetic and Non-Diabetic Rats
CNS & Neurological Disorders - Drug Targets Reliability of the Alzheimer’s Disease Assessment Scale (ADAS-Cog) in longitudinal Studies
Current Alzheimer Research The Effect of Acori Graminei Rhizoma and Extract Fractions on Spatial Memory and Hippocampal Neurogenesis in Amyloid Beta 1-42 Injected Mice
CNS & Neurological Disorders - Drug Targets Age-related Changes in Respiratory Function and Daily Living. A Tentative Model Including Psychosocial Variables, Respiratory Diseases and Cognition
Current Aging Science MicroRNAs in Atrial Fibrillation
Current Medicinal Chemistry Antiarrhythmic Therapy on Prevention of Postoperative Atrial Fibrillation in Patients After Heart Surgery
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Effects of Physical Exercise on Depressive Symptoms and Biomarkers in Depression
CNS & Neurological Disorders - Drug Targets Insulin-Degrading Enzyme: Structure-Function Relationship and its Possible Roles in Health and Disease
Current Pharmaceutical Design Metabolic Alterations in the Outer Membrane Vesicles of Patients with Alzheimer’s Disease: An LC-MS/MS-based Metabolomics Analysis
Current Alzheimer Research Lead Finding for Acetyl Cholinesterase Inhibitors from Natural Origin: Structure Activity Relationship and Scope
Mini-Reviews in Medicinal Chemistry Optimal Treatment of Severe Community-Acquired Pneumonia
Current Respiratory Medicine Reviews Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I
Current Neuropharmacology Increase of EEG Alpha3/Alpha2 Power Ratio Detects Inferior Parietal Lobule Atrophy in Mild Cognitive Impairment
Current Alzheimer Research Quinoline Derivatives: Candidate Drugs for a Class B G-Protein Coupled Receptor, the Calcitonin Gene-Related Peptide Receptor, a Cause of Migraines
CNS & Neurological Disorders - Drug Targets Differential Cued-Stroop Performance in Cognitively Asymptomatic Older Adults with Biomarker-Identified Risk for Alzheimer’s Disease: A Pilot Study
Current Alzheimer Research